Intensive glucose control after allogeneic hematopoietic stem cell transplantation: A retrospective matched-cohort study

S. Fuji, S. W. Kim, S. Mori, S. Kamiya, K. Yoshimura, H. Yokoyama, S. Kurosawa, B. Saito, T. Takahashi, S. Kuwahara, Y. Heike, R. Tanosaki, Y. Takaue, T. Fukuda

研究成果: Article査読

22 被引用数 (Scopus)

抄録

Some studies have shown that intensive glucose control (IGC) improves outcome in the intensive care unit setting. However, it is the benefit of IGC in hematopoietic SCT (HSCT) that is not well defined. Between June 2006 and May 2007, IGC was maintained prospectively after allogeneic HSCT and clinical outcomes were compared with a cohort matched for conditioning regimen, source of stem cells, age and relation to donor. A stratified Cox regression model was used. There were no significant differences in baseline clinical characteristics. The median age was 43.5 years in both groups. The primary diagnosis was a hematologic malignancy. Patients in the IGC group had a lower glucose level (least-square mean, 116.4 vs 146.8 mg per 100 ml, P <0.001) compared to the standard glucose control group. The incidences of documented infections and bacteremia were significantly lower in the IGC group (14 vs 46%, P = 0.004, 9 vs 39%, P = 0.002, respectively). IGC tended to reduce the incidence of renal dysfunction (19 vs 37%, P = 0.36) and the elevation of C-reactive protein (18 vs 38%, P = 0.13). This study suggests that IGC has may have a beneficial effect after HSCT. IGC should be evaluated further in a large prospective, randomized study.

本文言語English
ページ(範囲)105-111
ページ数7
ジャーナルBone Marrow Transplantation
44
2
DOI
出版ステータスPublished - 2009
外部発表はい

ASJC Scopus subject areas

  • Hematology
  • Transplantation

フィンガープリント 「Intensive glucose control after allogeneic hematopoietic stem cell transplantation: A retrospective matched-cohort study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル